135 related articles for article (PubMed ID: 9674749)
21. Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia.
Kahl C; Florschütz A; Müller G; Jentsch-Ullrich K; Arland M; Leuner S; Franke A; Höffkes HG
Ann Hematol; 1997 Sep; 75(3):91-4. PubMed ID: 9368477
[TBL] [Abstract][Full Text] [Related]
22. Acute myeloblastic leukemia with trilineage myelodysplasia and CD34+ blast cells with abnormal chromatin clumping.
Gil S; Luño E; Rodriguez JA
Haematologica; 1998 Aug; 83(8):750-1. PubMed ID: 9793262
[TBL] [Abstract][Full Text] [Related]
23. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Parker JE; Pagliuca A; Mijovic A; Cullis JO; Czepulkowski B; Rassam SM; Samaratunga IR; Grace R; Gover PA; Mufti GJ
Br J Haematol; 1997 Dec; 99(4):939-44. PubMed ID: 9432047
[TBL] [Abstract][Full Text] [Related]
24. [Low-dose chemotherapy].
Ogata K; Yamada T; Dan K
Rinsho Ketsueki; 1996 Sep; 37(9):777-81. PubMed ID: 8914461
[TBL] [Abstract][Full Text] [Related]
25. Reasons for treating secondary AML as de novo AML.
Ostgård LS; Kjeldsen E; Holm MS; Brown Pde N; Pedersen BB; Bendix K; Johansen P; Kristensen JS; Nørgaard JM
Eur J Haematol; 2010 Sep; 85(3):217-26. PubMed ID: 20456491
[TBL] [Abstract][Full Text] [Related]
26. Not the presence but the amount of clonal DNA detectable in remission of acute myeloid leukemia is predictive for relapse.
Reif SW; Wiesner D; Duell T; Mittermueller J; Schmetzer HM
Eur J Haematol; 2001 Oct; 67(4):207-20. PubMed ID: 11860441
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
28. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
29. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
[TBL] [Abstract][Full Text] [Related]
30. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Schoch C; Haferlach T; Haase D; Fonatsch C; Löffler H; Schlegelberger B; Staib P; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
Br J Haematol; 2001 Jan; 112(1):118-26. PubMed ID: 11167792
[TBL] [Abstract][Full Text] [Related]
31. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia.
Liu Yin JA; Johnson PR; Davies JM; Flanagan NG; Gorst DW; Lewis MJ
Br J Haematol; 1991 Nov; 79(3):415-20. PubMed ID: 1751369
[TBL] [Abstract][Full Text] [Related]
32. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
[TBL] [Abstract][Full Text] [Related]
33. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
De Witte T; Muus P; De Pauw B; Haanen C
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
[TBL] [Abstract][Full Text] [Related]
34. High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
Petti MC; Tafuri A; Latagliata R; Aloe Spiriti MA; Montefusco E; Mancini M; Meloni G; Petrucci MT; Spadea A; Redi R; Alimena G; Mandelli F
Ann Hematol; 2003 Aug; 82(8):476-480. PubMed ID: 12835916
[TBL] [Abstract][Full Text] [Related]
35. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
Hoyle CF; de Bastos M; Wheatley K; Sherrington PD; Fischer PJ; Rees JK; Gray R; Hayhoe FG
Br J Haematol; 1989 May; 72(1):45-53. PubMed ID: 2736242
[TBL] [Abstract][Full Text] [Related]
36. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.
Armitage JO; Carbone PP; Connors JM; Levine A; Bennett JM; Kroll S
J Clin Oncol; 2003 Mar; 21(5):897-906. PubMed ID: 12610191
[TBL] [Abstract][Full Text] [Related]
37. Trisomy 11: an association with stem/progenitor cell immunophenotype.
Slovak ML; Traweek ST; Willman CL; Head DR; Kopecky KJ; Magenis RE; Appelbaum FR; Forman SJ
Br J Haematol; 1995 Jun; 90(2):266-73. PubMed ID: 7794746
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
[TBL] [Abstract][Full Text] [Related]
39. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
[TBL] [Abstract][Full Text] [Related]
40. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group.
Taylor PR; Reid MM; Stark AN; Bown N; Hamilton PJ; Proctor SJ
Leukemia; 1995 Feb; 9(2):231-7. PubMed ID: 7532766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
